Recall Register

Food, drugs, devices › Akorn, Inc.

Drug recall: Atropine Sulfate Ophthalmic 1% Solution, USP, 5mL per bottle, Sterile, Rx Only, Manufactured by: Akorn, Inc., Lake Fores

FDA enforcement event 79278 · Class III · initiated 21 Feb 2018 · status Terminated · terminated 31 Aug 2020

DrugVoluntary: Firm initiated1 product recordLake Forest, IL

Akorn, Inc. (Lake Forest, IL) initiated this drug recall on 21 Feb 2018; FDA lists 1 product record under event 79278, classified Class III.

FDA defines Class III as a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences. 29% of the 367 drug enforcement events initiated in 2018 carry the same class.

Status: Terminated, terminated 31 Aug 2020. Initiation: voluntary: firm initiated. Akorn, Inc. has 65 enforcement events on this register, with a median of 1 product record per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

Akorn, Inc., Lake Forest, IL.

Reason for recall

"Failed Stability Specification: OOS low viscosity results discovered during retain testing."

Distribution

"Nationwide in the USA"

Product records

Recall numberProductQuantityClassStatusReport date
D-0577-2018Atropine Sulfate Ophthalmic 1% Solution, USP, 5mL per bottle, Sterile, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. NDC: 17478-215-0531,812 bottlesClass IIITerminated14 Mar 2018

Context

29%of 2018 drug events are Class III367 events that year
1product record in this eventfirm median: 1
65events on this register for the firm

Other enforcement events for Akorn, Inc.

InitiatedProduct (first record)TypeClassRecords
26 Apr 2023Atropine Sulfate Ophthalmic Solution, USP 1%, For Topical Application To The Eye, packaged in a) 2 mL bottles b) 5 mL boDrugClass II86
30 Jan 2023Atropine Sulfate Ophthalmic Solution, USP 1%, For Topical Application To The Eye, 2 mL bottle, Sterile, Rx only, DistribDrugClass III1
13 Oct 2022AK-POLY-BAC brand of Bacitracin cand Polymixin B Sulfate Ophthalmic Ointment USP, 3.5 g (1/8 oz.) tube, Rx only, SterileDrugClass II27
21 Sep 2022Rifampin Capsules, USP, 150 mg, 30-count bottle, Rx only, Distributed by: Akorn Operating Company, LLC, Gurnee, IL 60031DrugClass II2
31 Aug 2022Lidocaine Hydrochloride Jelly USP, 2%, Sterile, 30mL tube, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045,DrugClass II2
8 Aug 2022Timolol Maleate Ophthalmic Solution, USP, 0.5%, 5 x 0.3 mL Single-Dose Vials, Rx Only, Sterile, Manufactured for: Akorn,DrugClass III1
1 Aug 2022PrednisoLONE Oral Solution USP, 15 mg per 5 mL, 240 ml bottle, Rx Only, HI-TECH PHARMACAL CO., INC., Amityville, NY 1170DrugClass II1
13 Jun 2022Fluticasone Propionate Nasal Spray, USP, 50 mcg, 16 g net fill weight per amber glass bottle, Rx only, Manufactured by: DrugClass II1
10 Jun 2022Calcipotriene Topical Solution, 0.005% (Scalp Solution), Rx only, 60 mL (2 fl. oz.) bottle, Manufactured by: HI-TECH PHADrugClass II1
15 Apr 2022Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2%, 100 mL per bottle, Rx only, Manufactured by Hi-Tech PhaDrugClass III1

All 65 events for Akorn, Inc.

Questions and answers

Why was this drug recalled?

FDA's record gives the reason for recall as: "Failed Stability Specification: OOS low viscosity results discovered during retain testing."

What does Class III mean?

FDA classifies recalls by relative degree of health hazard. Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.

Where was the product distributed?

FDA's distribution pattern field reads: "Nationwide in the USA"

Is the recall still ongoing?

FDA lists the status as Terminated; the termination date is 31 Aug 2020. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.